US green light for Incyte
The FDA has just granted marketing authorization to Zynyz (retifanlimab-dlwr) from American biotech Incyte, for the treatment of locally advanced metastatic or recurrent Merkel cell carcinoma, a rare and aggressive type of skin cancer. In phase III trials, patients treated with this monoclonal antibody achieved an objective response rate of 52%. Zynyz is also being studied in other indications, alone or in combination.
VOS INDICES
source
Novartis advances in breast cancer
The Swiss laboratory has communicated new data on the phase III trial evaluating the Kisqali (ribociclib) in a large population of patients with early stage breast cancer. The study met its primary endpoint by demonstrating a clinically meaningful benefit to patients compared to standard therapy. Kisqali is an inhibitor already approved once morest advanced or metastatic breast cancer.
European authorization for BMS
The Sotyktu (deucravacitinib) of Bristol Myers Squibb (BMS) has been approved in Europe as an oral treatment for adult patients with moderate to severe plaque psoriasis who are eligible for systemic therapy. In its Phase III phase, this tyrosine kinase 2 (TYK2) inhibitor was shown to be more effective than placebo and Amgen’s Otezla (apremilast) at 16 and 24 weeks, with responses maintained for one year.
Selected for you
